loader2
Partner With Us NRI

Company details

1,020.55
1,040.35
1,000.00
2,309.65
6M Return -39.34%
1Y Return -53.71%
Mkt Cap.(Cr) 1,319.37
Volume 3,283
Div Yield 0.49%
OI
-
OI Chg %
-
Volume 3,283

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 786.46 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,806.36 -39,994.59
LAST 3M 79,235.45 -52,306.79
LAST 6M 143,739.24 -201,556.99
LAST 12M 206,053.08 -176,593.86
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
Jun 29, 2021 Dividend 30
Nov 10, 2020 Dividend 20
Feb 18, 2020 Dividend 20

Information

  • About Company
  • Company Info
  • Listing Info
20.64
36.22%
654.4024
11.1%
9.48%
Description
  • Set up in 1984 as a private limited company to manufacture bulk drugs, Neuland Laboratories (NLL) is promoted by D R Rao. Neuland Drugs & Pharmaceuticals Pvt Ltd, a company set up by the same promoters to manufacture bulk drugs was merged with NLL with effect from Apr.`92. NLL manufactures bulk drugs such as salbutamol sulphate, terbutaline sulphate, labetalol hydrochloride and ciprofloxacin. It came out with its initial public offering in Apr.`94 at a premium of Rs 35 aggregating Rs 5.69 cr, to part-finance the capacity expansion to manufacture bulk drugs and to diversify its product-mix. The cost of the project as estimated by ICICI was Rs 15.7 cr. NLL`s products are exported to more than 35 countries including Germany, Italy, Switzerland, the UK and the Netherlands. The company is also negotiating with multinational companies for tying up supplies of Ranitidine Hydrochloride Form I and Salbutamol Sulphate. During the year 1999-2000, the company introduced Itraconazole, an anti-fungal drug and Ipratropium Bromide, an anti-asthmatic drug and the R & D has developed a process for manufacture of Oflaxacin for Regulatory Markets. The Pashamylaram unit has received USFDA approval for manufacturing of Rantidine Hydrochloride Form. Mirtrazapine, an anti-depressive drug and Ramipril a cardiovascular drug were introduced during the year 2001.The installed capacities of Ciprofloxacin and Ranitidine were increased with Rs.650 lacs financial assisitance from IDBI. The company is closely working with several companies in Europe and North America for supply of active pharmaceutical ingredients and intermediates.

Read More

Registered Address

11 Th Floor Phoenix IVY Buildi, Plot No 573A-III Road No 82, Hyderabad, Telangana, 500035

Tel : 91-40-30211600
Email : ir:neulandlabs.com
Website : http://www.neulandlabs.com

Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Jul
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 524558
NSE Code : NEULANDLAB
Book Closure Date (Month) : Jul
BSE Group : T
ISIN : INE794A01010

ICICIdirect Neuland Laboratories Ltd FAQ

You can buy Neuland Laboratories Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Neuland Laboratories Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 20, 2022 04:01 PM the closing price of Neuland Laboratories Ltd was ₹ 1,028.35.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 20, 2022 04:01 PM, the market cap of Neuland Laboratories Ltd stood at ₹ 1,319.37.
The latest PE ratio of Neuland Laboratories Ltd as of May 20, 2022 04:01 PM is 20.64
The latest PB ratio of Neuland Laboratories Ltd as of May 20, 2022 04:01 PM is 0.64
The 52-week high of Neuland Laboratories Ltd is ₹ 2,309.65 while the 52-week low is ₹ 1,000.00 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE